1. "Myeloma"
Formats
  1. Meeting Abstract (543)
  2. Journal Article (358)
  3. Review (36)
  4. Research Letter (19)
  5. Book Section (10)
  6. Guidelines (10)
  7. Correspondence (6)
  8. Editorial (5)
  9. Conference Paper (1)
Groups
  1. Center for Hematologic Malignancies (988)
  2. Department of Medicine (988)
  3. Hematologic Malignancies, Division of (988)
  4. Myeloma (988)
  5. Hematologic Malignancies Research (651)
  6. Survivorship Research (356)

More Groups

People
  1. Alexander Lesokhin (363)
  2. Carl Landgren (336)
  3. Hani Hassoun (329)
  4. Sham Mailankody (282)
  5. Malin Hultcrantz (260)
  6. Heather Landau (239)

More People

Years
  1. 2025 (13)
  2. 2024 (69)
  3. 2023 (115)
  4. 2022 (96)
  5. 2021 (76)
  6. 2020 (95)

More Years

Publications
  1. Blood (303)
  2. Clinical Lymphoma, Myeloma and Leukemia (96)
  3. Journal of Clinical Oncology (85)
  4. Haematologica (41)
  5. Biology of Blood and Marrow Transplantation (29)
  6. Blood Cancer Journal (22)

More Publications

Publishers
  1. American Society of Hematology (324)
  2. Elsevier Inc. (159)
  3. American Society of Clinical Oncology (87)
  4. Nature Publishing Group (83)
  5. Ferrata Storti Foundation (41)
  6. American Association for Cancer Research (34)

More Publishers

Results (988)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Circulating tumor plasma cells in the screened iStopMM smoldering multiple myeloma cohort
    Meeting Abstract

    Thorsteinsdóttir, S.; Oskarsson, J. Þ.; Rögnvaldsson, S.; Gíslason, G.; Aspelund, T.; Sigurdardottir, G. Á; Thordardottir, Á. R.; Vidarsson, B.; Onundarson, P. T.; Agnarsson, B. A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: Final analysis of the DREAMM-2 trial
    Meeting Abstract

    Nooka, A. K.; Cohen, A.; Lee, H. C.; Badros, A. Z.; Suvannasankha, A.; Callander, N.; Abdallah, A. O.; Trudel, S.; Chari, A.; Libby, E.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Initial results of dose escalation of ISB 1342, a novel CD3xCD38 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM)
    Meeting Abstract

    Mohan, S. R.; Chase, C. C.; Berdeja, J. G.; Karlin, L.; Belhadj, K.; Perrot, A.; Moreau, P.; Touzeau, C.; Chalopin, T.; Lesokhin, A. M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Belantamab mafodotin in patients with relapsed/refractory multiple myeloma, a real-world single center experience
    Meeting Abstract

    Hultcrantz, M.; Derkach, A.; Hassoun, H.; Korde, N.; Maclachlan, K. H.; Mailankody, S.; Patel, D.; Shah, U. A.; Tan, C.; Akhlaghi, T.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Patterns of childbirth in women with myeloproliferative neoplasms
    Meeting Abstract

    Landtblom, A. R.; Andersson, T. M. L.; Johansson, A. L. V.; Lundberg, F. E.; Samuelsson, J.; Björkholm, M.; Hultcrantz, M.
    Blood (2022)

    Fulltext@MSK | Save
  • A randomized placebo controlled study of a plant-based dietary versus supplement versus placebo intervention in patients with monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) - the Nutrition Prevention (NUTRIVENTION-3) study
    Meeting Abstract

    Shah, U. A.; Castro, F.; Anuraj, A.; Schach, E.; Derkach, A.; Joseph, N. S.; Adintori, P. A.; Guttentag, L.; Blaslov, J.; Cross, J. R.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A pilot plant based dietary intervention in MGUS and SMM patients with elevated BMI is feasible and associated with improvements in metabolic and microbiome biomarkers of progression
    Meeting Abstract

    Shah, U. A.; Derkach, A.; Castro, F.; Anuraj, A.; Blaslov, J.; Tran, L.; Adintori, P. A.; Burge, M.; Funkhouser, S.; Hosszu, K.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Multivariable analyses of prognostic factors for progression-free survival (PFS) and complete response (CR) with lenalidomide, bortezomib, and dexamethasone (RVd) alone versus RVd plus autologous stem cell transplantation (ASCT) in patients (Pts) with newly diagnosed multiple myeloma (NDMM) in the DETERMINATION phase 3 trial
    Meeting Abstract

    Hassoun, H.; Jacobus, S. J.; Richardson, P. G.; Zonder, J. A.; Voorhees, P. M.; Kaufman, J. L.; Yee, A. J.; Scott, E. C.; Torka, P.; Libby, E.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Universal updated phase 1 data highlights role of allogeneic anti-BCMA ALLO-715 therapy for relapsed/refractory multiple myeloma
    Meeting Abstract

    Mailankody, S.; Matous, J. V.; Liedtke, M.; Sidana, S.; Oluwole, O. O.; Mohan, M.; Cruz, J. C.; Nath, R.; Anwer, F.; Rossi, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Enduring responses after 1-year, fixed-duration cevostamab therapy in patients with relapsed/refractory multiple myeloma: Early experience from a phase I study
    Meeting Abstract

    Lesokhin, A. M.; Richter, J.; Trudel, S.; Cohen, A. D.; Spencer, A.; Forsberg, P. A.; Laubach, J. P.; Thomas, S. K.; Bahlis, N. J.; Costa, L. J.; more...
    Blood (2022)

    Fulltext@MSK | Save